Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyfuse Biomedical KKFSE:4892 31 PB Ratio is 1.91 as of Jul. 18, 2026, which is 5% below its 10-year median of 2.00. GuruFocus rates FSE:4892 with a GF Score™ of 31/100 and a GF Value™ of 円2,172.95. The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 50.98% on this metric.
The historical rank and industry rank for Cyfuse Biomedical KK's PB Ratio or its related term are showing as below:
FSE:4892'
s PB Ratio Range Over the Past 10 Years
Min: 1.25 Med: 2 Max: 4.25
Current: 1.91
During the past 6 years, Cyfuse Biomedical KK's highest PB Ratio was 4.25. The lowest was 1.25. And the median was 2.00.
FSE:4892's PB Ratio is ranked worse than 50.98% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs FSE:4892: 1.91
During the past 12 months, Cyfuse Biomedical KK's average Book Value Per Share Growth Rate was -7.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.00% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Cyfuse Biomedical KK was 23.40% per year. The lowest was -16.10% per year. And the median was 5.40% per year.
Back to Basics: PB Ratio
Cyfuse Biomedical KK (FSE:4892) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cyfuse Biomedical KK PB Ratio Related Terms
Cyfuse Biomedical KK PB Ratio Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cyfuse Biomedical KK (FSE:4892) has a PB Ratio of 1.91 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cyfuse Biomedical KK and its competitors. This is near median its historical median of 2.00. Over the past decade, Cyfuse Biomedical KK's PB Ratio has ranged from 1.25 to 4.25. According to the industry distribution chart, Cyfuse Biomedical KK ranks #470 out of 922 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is Cyfuse Biomedical KK's PB Ratio too high?
Cyfuse Biomedical KK's current PB Ratio of 1.91 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 4.25. The Drug Manufacturers industry median PB Ratio is 1.91. Cyfuse Biomedical KK's value of 1.91 is 0% at this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #470 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cyfuse Biomedical KK has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's PB Ratio compare to ?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #470 out of 922 companies for PB Ratio. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median PB Ratio is 1.91. Cyfuse Biomedical KK's value of 1.91 is 0% at this benchmark. Historically, Cyfuse Biomedical KK's own PB Ratio has ranged from 1.25 to 4.25 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 1.91, Cyfuse Biomedical KK has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current PB Ratio of 1.91 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current PB Ratio is 1.91, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Cyfuse Biomedical KK (FSE:4892) has a current PB Ratio of 1.91. The stock's GF Value™ is 円2,172.95, compared to a current price of 円527.00 — trading 75.7% below its estimated fair value. The current PB Ratio is 1.91, which is near median its 10-year median of 2.00 and 0% at the Drug Manufacturers industry median of 1.91. Cyfuse Biomedical KK's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current PB Ratio is 1.91 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円527.00 is trading 75.7% below its estimated GF Value™ of 円2,172.95.
Key valuation signals for FSE:4892:
PB Ratio: 1.91 (near median its 10-year median of 2.00)
GF Value™: 円2,172.95 vs. price of 円527.00 (75.7% below fair value)
Industry Position: 0% at the Drug Manufacturers median (#470 of 922)
No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
31GF Score
Get the complete analysis for FSE:4892
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4892 has been successfully added to your 
